Charles Cantor, Sequenom, Inc., “Detecting specific nucleic acid sequences under challenging but potentially useful circumstances.”
Chief Scientific Officer, Sequenom, Inc.
Professor, Biomedical Engineering, Boston University
Professor of Pharmacology, School of Medicine, Boston University
Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc. He is also founder of SelectX Pharmaceuticals, a drug discovery company based in the Boston area; Retrotope, an anti-aging company; and DiThera, a biotherapeutic company. He is co-director of the Center for Advanced Biotechnology at Boston University, and professor emeritus of Biomedical Engineering. Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was also director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. He has published more than 450 peer-reviewed articles, has been granted more than 60 patents. He co-authored a three-volume textbook on Biophysical Chemistry and the first textbook on Genomics: The Science and Technology of the Human Genome Project. He sits on the advisory boards of more than 15 national and international organizations and is a member of the National Academy of Sciences.